Researchers found that early treatment with plasma from recovered COVID-19 patients reduces the risk of developing post-COVID conditions or "long COVID." The study revealed that patients who received the plasma, rich in SARS-CoV-2 antibodies, had a reduced hospitalization rate and fewer long COVID symptoms compared to those receiving a placebo.